

GLYCINE TRANSPORTER-1 INHIBITORS**Abstract**

The present invention provides compounds of formula (I) that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT-1 such as cognitive disorders associated with Schizophrenia, **ADHD** (attention deficit hyperactivity disorder), **MCI** (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

[No suitable figure]